ChemoMetec A/S (FRA:CHY)

Market Cap	1.36B -14.3%
Revenue (ttm)	68.36M +3.1%
Net Income	27.00M +15.5%
EPS	1.55 +15.6%
Shares Out	n/a
PE Ratio	50.87
Forward PE	45.84
Dividend	0.94 (1.19%)
Ex-Dividend Date	Oct 10, 2025

Volume	4
Open	78.95
Previous Close	78.90
Day's Range	78.95 - 78.95
52-Week Range	33.74 - 106.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 174
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CHY

Financial Performance

In fiscal year 2026, ChemoMetec's revenue was 511.06 million, an increase of 3.12% compared to the previous year's 495.57 million. Earnings were 201.84 million, an increase of 15.53%.

Financial numbers in DKK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error